Status:
COMPLETED
Sitagliptin Added-on to Insulin Study (0431-051)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
21+ years
Phase:
PHASE3
Brief Summary
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
Eligibility Criteria
Inclusion
- Patient has type 2 diabetes mellitus
- Patient is poorly controlled while on insulin or insulin and metformin
Exclusion
- Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
- Patient is taking oral antidiabetic agents other than metformin during the past 3 months
- Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin
Key Trial Info
Start Date :
December 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2008
Estimated Enrollment :
641 Patients enrolled
Trial Details
Trial ID
NCT00395343
Start Date
December 11 2006
End Date
October 13 2008
Last Update
May 12 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.